The Global Psychedelic Drugs Market Size accounted for USD 2.6 Billion in 2022 and is estimated to achieve a market size of USD 7.1 Billion by 2032 growing at a CAGR of 10.9% from 2023 to 2032.
Psychedelic Drugs Market Highlights
- Global psychedelic drugs market revenue is poised to garner USD 7.1 billion by 2032 with a CAGR of 10.9% from 2023 to 2032
- North America psychedelic drugs market value occupied more than USD 1.7 billion in 2022
- As per a 2021 survey, approximately 21% American adults experienced mental illness
- Asia-Pacific psychedelic drugs market growth will record a CAGR of more than 11% from 2023 to 2032
- Among therapeutic drugs, the psilocybin sub-segment generated around US$ 1.1 billion revenue in 2022
- Based on distribution channel, the hospital pharmacies sub-segment generated around 56% share in 2022
- Development of new delivery methods is a popular psychedelic drugs market trend that fuels the industry demand
Psychedelic drugs are a type of medication that alters perception, mood, and cognitive functions. For centuries, these drugs were used for religious and spiritual purposes, and they have recently been studied for their potential medicinal benefits in the treatment of mental health conditions like depression, anxiety, and PTSD. One of the primary benefits of psychedelic drugs is their ability to induce altered states of consciousness, which can allow patients gain new insights and viewpoints on their thoughts, emotions, and behavior. This can be especially helpful for patients suffering from treatment-resistant mental health disorders, who may have few options for effective treatment.
Researchers, clinicians, and the general public have become increasingly interested in psychedelic drugs in recent years. As a result, there has been a surge in research into the therapeutic potential of psychedelic drugs, in addition to the development of new drugs and therapies in this field. A recent trend in the psychedelic drug industry is the growing acceptance and legalization of certain drugs for medical and therapeutic purposes. Psilocybin, for example, has been legalized or decriminalized in several states in the United States, and the FDA has classified MDMA-assisted therapy for PTSD as a breakthrough therapy.
Global Psychedelic Drugs Market Dynamics
Market Drivers
- Growing interest in alternative therapies for mental health disorders
- Increasing number of clinical trials studying the therapeutic potential of psychedelic drugs
- Rising acceptance of psychedelic drugs for medical and therapeutic use
- Legalization of psychedelic drugs in some countries
- Increasing prevalence of mental health disorders
Market Restraints
- Negative public perception and stigma surrounding psychedelic drugs
- Lack of FDA approval for most psychedelic drugs
- Limited research and knowledge of the long-term effects of psychedelic drugs
- Availability and access to psychedelic drugs, especially natural sources
- Potential abuse and addiction
Market Opportunities
- Potential for new and innovative treatments for mental health disorders
- Expansion of the psychedelic drugs market through increased acceptance and legalization
- Potential for new partnerships and collaborations in the pharmaceutical industry
- Increased public awareness and education about psychedelic drugs and their potential benefits
Psychedelic Drugs Market Report Coverage
| Market |
Psychedelic Drugs Market |
| Psychedelic Drugs Market Size 2022 |
USD 2.6 Billion |
| Psychedelic Drugs Market Forecast 2032 |
USD 7.1 Billion |
| Psychedelic Drugs Market CAGR During 2023 - 2032 |
10.9% |
| Psychedelic Drugs Market Analysis Period |
2020 - 2032 |
| Psychedelic Drugs Market Base Year |
2022 |
| Psychedelic Drugs Market Forecast Data |
2023 - 2032 |
| Segments Covered |
By Source, By Therapeutic Drugs, By Indication, By Route of Administration, By Distribution Channel, And By Geography
|
| Regional Scope |
North America, Europe, Asia Pacific, Latin America, and Middle East & Africa |
| Key Companies Profiled |
COMPASS, Cybin Corp., Entheon Biomedical Corp, F. Hoffmann-La Roche Ltd, Hikma Pharmaceuticals PLC, Jazz Pharmaceuticals, Inc., Janssen Global Services, LLC, Pfizer Inc., PharmaTher Holdings Ltd., and usonainstitute.org.
|
Report Coverage
|
Market Trends, Drivers, Restraints, Competitive Analysis, Player Profiling, Covid-19 Analysis, Regulation Analysis |
Psychedelic Drugs Market Insights
A variety of factors are expected to drive significant growth in the psychedelic drugs market in the coming years. The growing interest in alternative therapies for mental health disorders is one of the key drivers of this growth. The limitations of traditional treatments for conditions such as depression, anxiety, and post-traumatic stress disorder (PTSD) have resulted in an increase in demand for alternative options, including psychedelic drugs. Another significant motivator is the growing number of clinical trials investigating the therapeutic potential of psychedelic drugs. Interest in these drugs' potential benefits is likely to grow as researchers continue to study their effects on the brain and mental health disorders.
However, there are several impediments to the growth of the psychedelic drugs market. For example, negative public perception and stigma surrounding psychedelic drugs may limit their acceptance in mainstream medicine. Furthermore, the lack of FDA approval for the majority of psychedelic drugs, as well as limited research on their long-term effects, may make it difficult for pharma companies to develop and market these drugs.
Despite these obstacles, the psychedelic drugs market offers numerous opportunities for expansion. The development of new delivery methods for these drugs, for example, could broaden their potential uses and make them more accessible to patients. Partnerships and collaborations in the pharmaceutical industry may also aid in the development and commercialization of psychedelic drugs. Overall, the market for psychedelic drugs is expected to expand in the coming years as more studies are done and public acceptance of these drugs increases. However, before widespread adoption can occur, careful consideration must be given to the legal and moral consequences of their use, as well as potential risks and benefits.
Psychedelic Drugs Market Segmentation
The worldwide market for psychedelic drugs is split based on source, therapeutic drugs, indication, route of administration, distribution channel, and geography.
Psychedelic Drug Sources
According to our psychedelic drugs industry analysis, both natural and synthetic sources are significant segment. Natural sources of psychedelic drugs, such as peyote cactus, psilocybin mushrooms, and ayahuasca, have been used for spiritual and healing purposes by indigenous cultures for centuries. These natural sources are increasingly being investigated for their therapeutic potential in the treatment of mental health disorders such as depression, anxiety, and post-traumatic stress disorder (PTSD). The growing interest in natural sources and the potential benefits they provide may result in increased demand for these products.
Synthetic sources of psychedelic drugs, such as MDMA (3,4-methylenedioxymethamphetamine) and LSD (lysergic acid diethylamide), on the other hand, have been used in clinical trials and are being researched for potential therapeutic benefits. Synthetic drugs can be manufactured in large quantities and on a consistent basis, making them more usable for research and potential medical use.
Psychedelic Drug Therapeutic Drugs
- Psilocybin
- LSD
- MDMA
- DMT
- Ketamine
Psilocybin is the market's leading therapeutic drug, accounting for more than 40% of the market in 2022. Psilocybin is being researched for its potential use in the treatment of depression and end-of-life anxiety. LSD is being researched for its potential use in the treatment of anxiety disorders, depression, and addiction. MDMA is being researched for its potential use in the treatment of PTSD, anxiety, and depression. DMT is being researched for its ability to treat depression and anxiety, while Ketamine is being researched for its ability to treat treatment-resistant depression.
LSD is the second most popular psychedelic drug in the world. LSD has been investigated for its potential therapeutic benefits in the treatment of a variety of mental health disorders, including anxiety, depression, and addiction. LSD's therapeutic potential is gaining attention and research, and it has the potential to become a significant market if it acquires regulatory approval for medical or therapeutic use.
Psychedelic Drug Indications
- Alzheimer Dementia
- Anorexia and Obesity
- Anxiety
- Cluster Headaches
- Depressive Disorders
- Obsessive Compulsive Disorders
- Personality Disorder
- Post-Traumatic Stress Disorder
- Substance Abuse Disorders
- Terminal Cancer Distress
All of the above indications have been studied for psychedelic drugs' potential therapeutic benefits, and each drug type has distinctive characteristics that render it suitable for different types of therapy. Psilocybin and LSD, for example, are being studied for their potential for treating depressive disorders, anxiety, and PTSD. MDMA is being researched for its potential use in the treatment of PTSD, anxiety, and depression. Ketamine is being researched for its use in the treatment of treatment-resistant depression and cluster headaches. DMT is being researched for its potential use in the treatment of depression, anxiety, and addiction.
Psychedelic Drug Route of Administrations
- Oral
- Injectable
- Rectal
- Nasal
- Transdermal
The route of administration for psychedelic drugs would be determined by a number of factors, including the drug's properties, the intended therapeutic effect, patient comfort, and convenience, among others. Oral administration may be more convenient and less invasive than injectable administration. However, injectable administration may be necessary in cases where immediate effects are needed. Rectal administration may be used in cases where oral administration is not effective, while nasal administration may be used for drugs that are absorbed more efficiently through the nasal membrane.
Psychedelic Drug Distribution Channels
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
According to the psychedelic drugs market forecasts, hospital pharmacies may be the primary distribution channel for psychedelic drugs used in a hospital setting, such as ketamine for anaesthesia or depression treatment. Retail pharmacies may be the primary distribution channel for outpatient drugs, such as oral or transdermal formulations of psychedelic drugs used to treat mental health disorders. Online pharmacies may also become an important distribution channel for these drugs, especially for patients living in remote or underserved areas.
Psychedelic Drugs Market Regional Outlook
North America
Europe
- U.K.
- Germany
- France
- Spain
- Rest of Europe
Asia-Pacific
- India
- Japan
- China
- Australia
- South Korea
- Rest of Asia-Pacific
Latin America
- Brazil
- Mexico
- Rest of Latin America
The Middle East & Africa
- South Africa
- GCC Countries
- Rest of the Middle East & Africa (ME&A)
Psychedelic Drugs Market Regional Analysis
Some parts of the world, such as North America and Europe, have been more open to studying the therapeutic benefits of psychedelic drugs, with significant research and investment in this area. These areas may have a more established market for psychedelic drugs, with a greater number of clinical trials and higher patient and medical professional acceptance.
Other regions, such as Asia and the Middle East, may have more stringent regulatory environments or cultural attitudes that limit the growth of the psychedelic drug market. However, as more research on the potential therapeutic benefits of these drugs is conducted, these attitudes and regulations may change over time.
Psychedelic Drugs Market Players
Some of the top psychedelic drugs companies offered in the professional report include COMPASS, Cybin Corp., Entheon Biomedical Corp, F. Hoffmann-La Roche Ltd, Hikma Pharmaceuticals PLC, Jazz Pharmaceuticals, Inc., Janssen Global Services, LLC, Pfizer Inc., PharmaTher Holdings Ltd., and usonainstitute.org.
CHAPTER 1. Industry Overview of Psychedelic Drugs Market
1.1. Definition and Scope
1.1.1. Definition of Psychedelic Drugs
1.1.2. Market Segmentation
1.1.3. Years Considered for the Study
1.1.4. Assumptions and Acronyms Used
1.1.4.1. Market Assumptions and Market Forecast
1.1.4.2. Acronyms Used in Global Psychedelic Drugs Market
1.2. Summary
1.2.1. Executive Summary
1.2.2. Psychedelic Drugs Market By Source
1.2.3. Psychedelic Drugs Market By Therapeutic Drugs
1.2.4. Psychedelic Drugs Market By Indication
1.2.5. Psychedelic Drugs Market By Route of Administration
1.2.6. Psychedelic Drugs Market By Distribution Channel
1.2.7. Psychedelic Drugs Market By Region
CHAPTER 2. Research Approach
2.1. Methodology
2.1.1. Research Programs
2.1.2. Market Size Estimation
2.1.3. Market Breakdown and Data Triangulation
2.2. Data Source
2.2.1. Secondary Sources
2.2.2. Primary Sources
CHAPTER 3. Market Dynamics And Competition Analysis
3.1. Market Drivers
3.1.1. Driver 1
3.1.2. Driver 2
3.2. Restraints and Challenges
3.2.1. Restraint 1
3.2.2. Restraint 2
3.3. Growth Opportunities
3.3.1. Opportunity 1
3.3.2. Opportunity 2
3.4. Porter’s Five Forces Analysis
3.4.1. Bargaining Power of Suppliers
3.4.2. Bargaining Power of Buyers
3.4.3. Threat of Substitute
3.4.4. Threat of New Entrants
3.4.5. Degree of Competition
3.5. Market Concentration Ratio and Market Maturity Analysis of Psychedelic Drugs Market
3.5.1. Go To Market Strategy
3.5.1.1. Introduction
3.5.1.2. Growth
3.5.1.3. Maturity
3.5.1.4. Saturation
3.5.1.5. Possible Development
3.6. Technological Roadmap for Psychedelic Drugs Market
3.7. Value Chain Analysis
3.7.1. List of Key Manufacturers
3.7.2. List of Customers
3.7.3. Level of Integration
3.8. Regulatory Compliance
3.9. Competitive Landscape, 2022
3.9.1. Player Positioning Analysis
3.9.2. Key Strategies Adopted By Leading Players
CHAPTER 4. Psychedelic Drugs Market By Source
4.1. Introduction
4.2. Psychedelic Drugs Revenue By Source
4.2.1. Psychedelic Drugs Revenue (USD Billion) and Forecast, By Source, 2020-2032
4.2.2. Synthetic
4.2.2.1. Synthetic Market Revenue (USD Billion) and Growth Rate (%), 2020-2032
4.2.3. Natural
4.2.3.1. Natural Market Revenue (USD Billion) and Growth Rate (%), 2020-2032
CHAPTER 5. Psychedelic Drugs Market By Therapeutic Drugs
5.1. Introduction
5.2. Psychedelic Drugs Revenue By Therapeutic Drugs
5.2.1. Psychedelic Drugs Revenue (USD Billion) and Forecast, By Therapeutic Drugs, 2020-2032
5.2.2. Psilocybin
5.2.2.1. Psilocybin Market Revenue (USD Billion) and Growth Rate (%), 2020-2032
5.2.3. LSD
5.2.3.1. LSD Market Revenue (USD Billion) and Growth Rate (%), 2020-2032
5.2.4. MDMA
5.2.4.1. MDMA Market Revenue (USD Billion) and Growth Rate (%), 2020-2032
5.2.5. DMT
5.2.5.1. DMT Market Revenue (USD Billion) and Growth Rate (%), 2020-2032
5.2.6. Ketamine
5.2.6.1. Ketamine Market Revenue (USD Billion) and Growth Rate (%), 2020-2032
CHAPTER 6. Psychedelic Drugs Market By Indication
6.1. Introduction
6.2. Psychedelic Drugs Revenue By Indication
6.2.1. Psychedelic Drugs Revenue (USD Billion) and Forecast, By Indication, 2020-2032
6.2.2. Alzheimer Dementia
6.2.2.1. Alzheimer Dementia Market Revenue (USD Billion) and Growth Rate (%), 2020-2032
6.2.3. Anorexia and Obesity
6.2.3.1. Anorexia and Obesity Market Revenue (USD Billion) and Growth Rate (%), 2020-2032
6.2.4. Anxiety
6.2.4.1. Anxiety Market Revenue (USD Billion) and Growth Rate (%), 2020-2032
6.2.5. Cluster Headaches
6.2.5.1. Cluster Headaches Market Revenue (USD Billion) and Growth Rate (%), 2020-2032
6.2.6. Depressive Disorders
6.2.6.1. Depressive Disorders Market Revenue (USD Billion) and Growth Rate (%), 2020-2032
6.2.7. Obsessive Compulsive Disorders
6.2.7.1. Obsessive Compulsive Disorders Market Revenue (USD Billion) and Growth Rate (%), 2020-2032
6.2.8. Personality Disorder
6.2.8.1. Personality Disorder Market Revenue (USD Billion) and Growth Rate (%), 2020-2032
6.2.9. Post-Traumatic Stress Disorder
6.2.9.1. Post-Traumatic Stress Disorder Market Revenue (USD Billion) and Growth Rate (%), 2020-2032
6.2.10. Substance Abuse Disorders
6.2.10.1. Substance Abuse Disorders Market Revenue (USD Billion) and Growth Rate (%), 2020-2032
6.2.11. Terminal Cancer Distress
6.2.11.1. Terminal Cancer Distress Market Revenue (USD Billion) and Growth Rate (%), 2020-2032
CHAPTER 7. Psychedelic Drugs Market By Route of Administration
7.1. Introduction
7.2. Psychedelic Drugs Revenue By Route of Administration
7.2.1. Psychedelic Drugs Revenue (USD Billion) and Forecast, By Route of Administration, 2020-2032
7.2.2. Oral
7.2.2.1. Oral Market Revenue (USD Billion) and Growth Rate (%), 2020-2032
7.2.3. Injectable
7.2.3.1. Injectable Market Revenue (USD Billion) and Growth Rate (%), 2020-2032
7.2.4. Rectal
7.2.4.1. Rectal Market Revenue (USD Billion) and Growth Rate (%), 2020-2032
7.2.5. Nasal
7.2.5.1. Nasal Market Revenue (USD Billion) and Growth Rate (%), 2020-2032
7.2.6. Transdermal
7.2.6.1. Transdermal Market Revenue (USD Billion) and Growth Rate (%), 2020-2032
CHAPTER 8. Psychedelic Drugs Market By Distribution Channel
8.1. Introduction
8.2. Psychedelic Drugs Revenue By Distribution Channel
8.2.1. Psychedelic Drugs Revenue (USD Billion) and Forecast, By Distribution Channel, 2020-2032
8.2.2. Hospital Pharmacies
8.2.2.1. Hospital Pharmacies Market Revenue (USD Billion) and Growth Rate (%), 2020-2032
8.2.3. Retail Pharmacies
8.2.3.1. Retail Pharmacies Market Revenue (USD Billion) and Growth Rate (%), 2020-2032
8.2.4. Online Pharmacies
8.2.4.1. Online Pharmacies Market Revenue (USD Billion) and Growth Rate (%), 2020-2032
CHAPTER 9. North America Psychedelic Drugs Market By Country
9.1. North America Psychedelic Drugs Market Overview
9.2. U.S.
9.2.1. U.S. Psychedelic Drugs Revenue (USD Billion) and Forecast By Source, 2020-2032
9.2.2. U.S. Psychedelic Drugs Revenue (USD Billion) and Forecast By Therapeutic Drugs, 2020-2032
9.2.3. U.S. Psychedelic Drugs Revenue (USD Billion) and Forecast By Indication, 2020-2032
9.2.4. U.S. Psychedelic Drugs Revenue (USD Billion) and Forecast By Route of Administration, 2020-2032
9.2.5. U.S. Psychedelic Drugs Revenue (USD Billion) and Forecast By Distribution Channel, 2020-2032
9.3. Canada
9.3.1. Canada Psychedelic Drugs Revenue (USD Billion) and Forecast By Source, 2020-2032
9.3.2. Canada Psychedelic Drugs Revenue (USD Billion) and Forecast By Therapeutic Drugs, 2020-2032
9.3.3. Canada Psychedelic Drugs Revenue (USD Billion) and Forecast By Indication, 2020-2032
9.3.4. Canada Psychedelic Drugs Revenue (USD Billion) and Forecast By Route of Administration, 2020-2032
9.3.5. Canada Psychedelic Drugs Revenue (USD Billion) and Forecast By Distribution Channel, 2020-2032
9.4. North America PEST Analysis
CHAPTER 10. Europe Psychedelic Drugs Market By Country
10.1. Europe Psychedelic Drugs Market Overview
10.2. U.K.
10.2.1. U.K. Psychedelic Drugs Revenue (USD Billion) and Forecast By Source, 2020-2032
10.2.2. U.K. Psychedelic Drugs Revenue (USD Billion) and Forecast By Therapeutic Drugs, 2020-2032
10.2.3. U.K. Psychedelic Drugs Revenue (USD Billion) and Forecast By Indication, 2020-2032
10.2.4. U.K. Psychedelic Drugs Revenue (USD Billion) and Forecast By Route of Administration, 2020-2032
10.2.5. U.K. Psychedelic Drugs Revenue (USD Billion) and Forecast By Distribution Channel, 2020-2032
10.3. Germany
10.3.1. Germany Psychedelic Drugs Revenue (USD Billion) and Forecast By Source, 2020-2032
10.3.2. Germany Psychedelic Drugs Revenue (USD Billion) and Forecast By Therapeutic Drugs, 2020-2032
10.3.3. Germany Psychedelic Drugs Revenue (USD Billion) and Forecast By Indication, 2020-2032
10.3.4. Germany Psychedelic Drugs Revenue (USD Billion) and Forecast By Route of Administration, 2020-2032
10.3.5. Germany Psychedelic Drugs Revenue (USD Billion) and Forecast By Distribution Channel, 2020-2032
10.4. France
10.4.1. France Psychedelic Drugs Revenue (USD Billion) and Forecast By Source, 2020-2032
10.4.2. France Psychedelic Drugs Revenue (USD Billion) and Forecast By Therapeutic Drugs, 2020-2032
10.4.3. France Psychedelic Drugs Revenue (USD Billion) and Forecast By Indication, 2020-2032
10.4.4. France Psychedelic Drugs Revenue (USD Billion) and Forecast By Route of Administration, 2020-2032
10.4.5. France Psychedelic Drugs Revenue (USD Billion) and Forecast By Distribution Channel, 2020-2032
10.5. Spain
10.5.1. Spain Psychedelic Drugs Revenue (USD Billion) and Forecast By Source, 2020-2032
10.5.2. Spain Psychedelic Drugs Revenue (USD Billion) and Forecast By Therapeutic Drugs, 2020-2032
10.5.3. Spain Psychedelic Drugs Revenue (USD Billion) and Forecast By Indication, 2020-2032
10.5.4. Spain Psychedelic Drugs Revenue (USD Billion) and Forecast By Route of Administration, 2020-2032
10.5.5. Spain Psychedelic Drugs Revenue (USD Billion) and Forecast By Distribution Channel, 2020-2032
10.6. Rest of Europe
10.6.1. Rest of Europe Psychedelic Drugs Revenue (USD Billion) and Forecast By Source, 2020-2032
10.6.2. Rest of Europe Psychedelic Drugs Revenue (USD Billion) and Forecast By Therapeutic Drugs, 2020-2032
10.6.3. Rest of Europe Psychedelic Drugs Revenue (USD Billion) and Forecast By Indication, 2020-2032
10.6.4. Rest of Europe Psychedelic Drugs Revenue (USD Billion) and Forecast By Route of Administration, 2020-2032
10.6.5. Rest of Europe Psychedelic Drugs Revenue (USD Billion) and Forecast By Distribution Channel, 2020-2032
10.7. Europe PEST Analysis
CHAPTER 11. Asia Pacific Psychedelic Drugs Market By Country
11.1. Asia Pacific Psychedelic Drugs Market Overview
11.2. China
11.2.1. China Psychedelic Drugs Revenue (USD Billion) and Forecast By Source, 2020-2032
11.2.2. China Psychedelic Drugs Revenue (USD Billion) and Forecast By Therapeutic Drugs, 2020-2032
11.2.3. China Psychedelic Drugs Revenue (USD Billion) and Forecast By Indication, 2020-2032
11.2.4. China Psychedelic Drugs Revenue (USD Billion) and Forecast By Route of Administration, 2020-2032
11.2.5. China Psychedelic Drugs Revenue (USD Billion) and Forecast By Distribution Channel, 2020-2032
11.3. Japan
11.3.1. Japan Psychedelic Drugs Revenue (USD Billion) and Forecast By Source, 2020-2032
11.3.2. Japan Psychedelic Drugs Revenue (USD Billion) and Forecast By Therapeutic Drugs, 2020-2032
11.3.3. Japan Psychedelic Drugs Revenue (USD Billion) and Forecast By Indication, 2020-2032
11.3.4. Japan Psychedelic Drugs Revenue (USD Billion) and Forecast By Route of Administration, 2020-2032
11.3.5. Japan Psychedelic Drugs Revenue (USD Billion) and Forecast By Distribution Channel, 2020-2032
11.4. India
11.4.1. India Psychedelic Drugs Revenue (USD Billion) and Forecast By Source, 2020-2032
11.4.2. India Psychedelic Drugs Revenue (USD Billion) and Forecast By Therapeutic Drugs, 2020-2032
11.4.3. India Psychedelic Drugs Revenue (USD Billion) and Forecast By Indication, 2020-2032
11.4.4. India Psychedelic Drugs Revenue (USD Billion) and Forecast By Route of Administration, 2020-2032
11.4.5. India Psychedelic Drugs Revenue (USD Billion) and Forecast By Distribution Channel, 2020-2032
11.5. Australia
11.5.1. Australia Psychedelic Drugs Revenue (USD Billion) and Forecast By Source, 2020-2032
11.5.2. Australia Psychedelic Drugs Revenue (USD Billion) and Forecast By Therapeutic Drugs, 2020-2032
11.5.3. Australia Psychedelic Drugs Revenue (USD Billion) and Forecast By Indication, 2020-2032
11.5.4. Australia Psychedelic Drugs Revenue (USD Billion) and Forecast By Route of Administration, 2020-2032
11.5.5. Australia Psychedelic Drugs Revenue (USD Billion) and Forecast By Distribution Channel, 2020-2032
11.6. South Korea
11.6.1. South Korea Psychedelic Drugs Revenue (USD Billion) and Forecast By Source, 2020-2032
11.6.2. South Korea Psychedelic Drugs Revenue (USD Billion) and Forecast By Therapeutic Drugs, 2020-2032
11.6.3. South Korea Psychedelic Drugs Revenue (USD Billion) and Forecast By Indication, 2020-2032
11.6.4. South Korea Psychedelic Drugs Revenue (USD Billion) and Forecast By Route of Administration, 2020-2032
11.6.5. South Korea Psychedelic Drugs Revenue (USD Billion) and Forecast By Distribution Channel, 2020-2032
11.7. Rest of Asia-Pacific
11.7.1. Rest of Asia-Pacific Psychedelic Drugs Revenue (USD Billion) and Forecast By Source, 2020-2032
11.7.2. Rest of Asia-Pacific Psychedelic Drugs Revenue (USD Billion) and Forecast By Therapeutic Drugs, 2020-2032
11.7.3. Rest of Asia-Pacific Psychedelic Drugs Revenue (USD Billion) and Forecast By Indication, 2020-2032
11.7.4. Rest of Asia-Pacific Psychedelic Drugs Revenue (USD Billion) and Forecast By Route of Administration, 2020-2032
11.7.5. Rest of Asia-Pacific Psychedelic Drugs Revenue (USD Billion) and Forecast By Distribution Channel, 2020-2032
11.8. Asia Pacific PEST Analysis
CHAPTER 12. Latin America Psychedelic Drugs Market By Country
12.1. Latin America Psychedelic Drugs Market Overview
12.2. Brazil
12.2.1. Brazil Psychedelic Drugs Revenue (USD Billion) and Forecast By Source, 2020-2032
12.2.2. Brazil Psychedelic Drugs Revenue (USD Billion) and Forecast By Therapeutic Drugs, 2020-2032
12.2.3. Brazil Psychedelic Drugs Revenue (USD Billion) and Forecast By Indication, 2020-2032
12.2.4. Brazil Psychedelic Drugs Revenue (USD Billion) and Forecast By Route of Administration, 2020-2032
12.2.5. Brazil Psychedelic Drugs Revenue (USD Billion) and Forecast By Distribution Channel, 2020-2032
12.3. Mexico
12.3.1. Mexico Psychedelic Drugs Revenue (USD Billion) and Forecast By Source, 2020-2032
12.3.2. Mexico Psychedelic Drugs Revenue (USD Billion) and Forecast By Therapeutic Drugs, 2020-2032
12.3.3. Mexico Psychedelic Drugs Revenue (USD Billion) and Forecast By Indication, 2020-2032
12.3.4. Mexico Psychedelic Drugs Revenue (USD Billion) and Forecast By Route of Administration, 2020-2032
12.3.5. Mexico Psychedelic Drugs Revenue (USD Billion) and Forecast By Distribution Channel, 2020-2032
12.4. Rest of Latin America
12.4.1. Rest of Latin America Psychedelic Drugs Revenue (USD Billion) and Forecast By Source, 2020-2032
12.4.2. Rest of Latin America Psychedelic Drugs Revenue (USD Billion) and Forecast By Therapeutic Drugs, 2020-2032
12.4.3. Rest of Latin America Psychedelic Drugs Revenue (USD Billion) and Forecast By Indication, 2020-2032
12.4.4. Rest of Latin America Psychedelic Drugs Revenue (USD Billion) and Forecast By Route of Administration, 2020-2032
12.4.5. Rest of Latin America Psychedelic Drugs Revenue (USD Billion) and Forecast By Distribution Channel, 2020-2032
12.5. Latin America PEST Analysis
CHAPTER 13. Middle East & Africa Psychedelic Drugs Market By Country
13.1. Middle East & Africa Psychedelic Drugs Market Overview
13.2. GCC
13.2.1. GCC Psychedelic Drugs Revenue (USD Billion) and Forecast By Source, 2020-2032
13.2.2. GCC Psychedelic Drugs Revenue (USD Billion) and Forecast By Therapeutic Drugs, 2020-2032
13.2.3. GCC Psychedelic Drugs Revenue (USD Billion) and Forecast By Indication, 2020-2032
13.2.4. GCC Psychedelic Drugs Revenue (USD Billion) and Forecast By Route of Administration, 2020-2032
13.2.5. GCC Psychedelic Drugs Revenue (USD Billion) and Forecast By Distribution Channel, 2020-2032
13.3. South Africa
13.3.1. South Africa Psychedelic Drugs Revenue (USD Billion) and Forecast By Source, 2020-2032
13.3.2. South Africa Psychedelic Drugs Revenue (USD Billion) and Forecast By Therapeutic Drugs, 2020-2032
13.3.3. South Africa Psychedelic Drugs Revenue (USD Billion) and Forecast By Indication, 2020-2032
13.3.4. South Africa Psychedelic Drugs Revenue (USD Billion) and Forecast By Route of Administration, 2020-2032
13.3.5. South Africa Psychedelic Drugs Revenue (USD Billion) and Forecast By Distribution Channel, 2020-2032
13.4. Rest of Middle East & Africa
13.4.1. Rest of Middle East & Africa Psychedelic Drugs Revenue (USD Billion) and Forecast By Source, 2020-2032
13.4.2. Rest of Middle East & Africa Psychedelic Drugs Revenue (USD Billion) and Forecast By Therapeutic Drugs, 2020-2032
13.4.3. Rest of Middle East & Africa Psychedelic Drugs Revenue (USD Billion) and Forecast By Indication, 2020-2032
13.4.4. Rest of Middle East & Africa Psychedelic Drugs Revenue (USD Billion) and Forecast By Route of Administration, 2020-2032
13.4.5. Rest of Middle East & Africa Psychedelic Drugs Revenue (USD Billion) and Forecast By Distribution Channel, 2020-2032
13.5. Middle East & Africa PEST Analysis
CHAPTER 14. Player Analysis Of Psychedelic Drugs Market
14.1. Psychedelic Drugs Market Company Share Analysis
14.2. Competition Matrix
14.2.1. Competitive Benchmarking of key players by price, presence, market share, and R&D investment
14.2.2. New Product Launches and Product Enhancements
14.2.3. Mergers And Acquisition In Global Psychedelic Drugs Market
14.2.4. Partnership, Joint Ventures and Strategic Alliances/ Sales Agreements
CHAPTER 15. Company Profile
15.1. COMPASS
15.1.1. Company Snapshot
15.1.2. Business Overview
15.1.3. Financial Overview
15.1.3.1. Revenue (USD Billion), 2022
15.1.3.2. COMPASS 2022 Psychedelic Drugs Business Regional Distribution
15.1.4. Product /Service and Specification
15.1.5. Recent Developments & Business Strategy
15.2. Cybin Corp.
15.3. Entheon Biomedical Corp
15.4. F. Hoffmann-La Roche Ltd
15.5. Hikma Pharmaceuticals PLC
15.6. Jazz Pharmaceuticals, Inc.
15.7. Janssen Global Services, LLC
15.8. Pfizer Inc.
15.9. PharmaTher Holdings Ltd.
15.10. usonainstitute.org.
